Food-grade antimicrobials potentiate the antibacterial activity of 1,2-hexanediol

Yogiara,; Hwang, Seon-Yeong; Park, S; Hwang, Jae Kwan; Pan, Jae-Gu

doi:10.1111/lam.12398

Cited by 17 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 Decanediol elicits antimicrobial activity by depolarizing cytoplasmic membranes and disrupting P acnes cell membranes through the aliphatic alcohol of its chemical structure. 35 It also acts on the P acnes biofilm by inhibiting new biofilm formation and degrading the mature biofilm. 36 Thus, this might be a promising agent for acne treatment, as it specifically targets the causative bacteria.…”

Section: Discussionmentioning

confidence: 99%

Acne treatment efficacy of intense pulsed light photodynamic therapy with topical licochalcone A, l‐carnitine, and decanediol: A spilt‐face, double‐blind, randomized controlled trial

Wanitphakdeedecha

Tavechodperathum

Tantrapornpong

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background: Depending on disease severity, standard acne treatments can vary from topical to systemic therapy. However, poor compliance caused by adverse events and antibiotic resistance is a major cause of treatment failure. Aims: To determine the effectiveness of photodynamic therapy (PDT) with intense pulsed light (IPL) in the treatment of acne when combined with a cream containing licochalcone A, L-carnitine and decanediol (so-called, 'active formulation') versus PDT alone. Patients/Methods: Twenty-nine volunteers, aged 21-39 years (26 women and 3 men, mean age 29.41 ± 5.24 years), with mild to severe facial acne, were enrolled. Each subject's face sides were randomized in a split-face manner to either receive PDT (IPL with a 400-720 nm cutoff filter, at 4 sessions with two-week intervals) combined with the active formulation cream twice daily for 10 weeks on one face side; or PDT and the vehicle cream on the other side, with the same treatment protocol. Reduction in acne quantity, melanin index and erythema index were assessed 2 weeks after the second treatment (day 28), 1 week after the fourth treatment (day 49), and 1 month after the fourth treatment (day 70). Results: Compared to baseline, patients in the active formulation group demonstrated a faster onset of reduction in the number of lesions at 2 weeks after the second treatment (p=0.010 for inflammatory acne and p=0.001 for non-inflammatory acne). A significantly greater reduction in lesion count was observed in the active formulation group compared with the vehicle group at all timepoints of evaluation for noninflammatory acne (day 28, day 49, and day 70; p=0.003, 0.005 and 0.002 respectively), and at 1 month after the fourth treatment for inflammatory acne (p=0.036). Compared to the vehicle group, the melanin index of the active formulation group decreased significantly at 1 month after the fourth treatment (p=0.015).

show abstract

Section: Discussionmentioning

confidence: 99%

Acne treatment efficacy of intense pulsed light photodynamic therapy with topical licochalcone A, l‐carnitine, and decanediol: A spilt‐face, double‐blind, randomized controlled trial

Wanitphakdeedecha

Tavechodperathum

Tantrapornpong

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…There is only limited information in the literature regarding its action on the skin and its ability to act as a penetration enhancer has not been established. Duracher et al (2009) HEX is a solvent commonly used as a preservative in personal care products because of its antibacterial properties (Yogiara et al, 2015). Given its chemical structure, it might be assumed that, as for other 1,2 glycols, HEX is likely to penetrate the skin and increase permeant solubility in the SC.…”

Section: Permeation Studies Using Neat Solventsmentioning

confidence: 99%

Topical delivery of niacinamide: Influence of neat solvents

Iliopoulos¹,

Sil

Hossain³

et al. 2020

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Niacinamide (NIA) has been widely used in cosmetic and personal care formulations for several skin conditions. Permeation of topical NIA has been confirmed in a number of studies under infinite dose conditions. However, there is limited information in the literature regarding permeation of NIA following application of topical formulations in amounts that reflect the real-life use of such products by consumers. The aim of the present work was therefore to investigate skin delivery of NIA from single solvent systems in porcine skin under finite dose conditions. A secondary aim was to probe the processes underlying the previously reported low recovery of NIA following in vitro permeation and mass balance studies. The solubility and stability of NIA in various single solvent systems was examined.The solvents investigated included Transcutol® P (TC), propylene glycol (PG), 1-2 hexanediol (HEX), 1-2 pentanediol (1-2P), 1-5 pentanediol (1-5P), 1-3 butanediol (1-3B), glycerol (GLY) and dimethyl isosorbide (DMI). Skin permeation and deposition of the molecule was investigated in full thickness porcine skin in vitro finite dose Franz-type diffusion experiments followed by mass balance studies. Stability of NIA for 72 h in the solvents was confirmed. The solubility of NIA in the solvents ranged from 82.9 ± 0.8 to 311.9 ± 4.5 mg/mL. TC delivered the highest percentage permeation of NIA at 24 h, 32.6 ± 12.1 % of the applied dose. Low total recovery of NIA after mass balance studies was observed for some vehicles, with values ranging from 55.2 ± 12.8 % to 106.3 ± 2.3 %. This reflected the formation of a number of NIA degradation by-products in the receptor phase during the permeation studies. Identification of other vehicles for synergistic enhancement of NIA skin delivery will be the subject of future work.

show abstract

“…When macelignan was combined with miconazole, each compensated the other’s weakness, showing a synergistic effect. Macelignan, as a food-grade antimicrobial compound, would minimally influence the eco-system ( 40 ) and could be a good candidate for the treatment of bee diseases caused by microorganisms. However, macelignan is not inexpensive enough to be solely used compared with miconazole.…”

Section: Discussionmentioning

confidence: 99%

Macelignan inhibits bee pathogenic fungi Ascophaera apis growth through HOG1 pathway

Shin

Kim

2016

Braz J Med Biol Res

View full text Add to dashboard Cite

Ascosphaera apis is a bee pathogen that causes bee larvae infection disease, to which treatment is not yet well investigated. The aim of this study was to investigate antifungal susceptibility in vitro against A. apis and to identify a new antifungal agent for this pathogen through minimal inhibitory concentration (MIC) assay and western blot analysis. Macelignan had 1.56 and 3.125 μg/mL MIC against A. apis after 24 and 48 h, respectively, exhibiting the strongest growth inhibition against A. apis among the tested compounds (corosolic acid, dehydrocostus lactone, loganic acid, tracheloside, fangchinoline and emodin-8-O-β-D-glucopyranoside). Furthermore, macelignan showed a narrow-ranged spectrum against various fungal strains without any mammalian cell cytotoxicity. In spite of miconazole having powerful broad-ranged anti-fungal activity including A. apis, it demonstrated strong cytotoxicity. Therefore, even if macelignan alone was effective as an antifungal agent to treat A. apis, combined treatment with miconazole was more useful to overcome toxicity, drug resistance occurrence and cost effectiveness. Finally, HOG1 was revealed as a target molecule of macelignan in the anti-A. apis activity by inhibiting phosphorylation using S. cerevisiae as a model system. Based on our results, macelignan, a food-grade antimicrobial compound, would be an effective antifungal agent against A. apis infection in bees.

show abstract

Food-grade antimicrobials potentiate the antibacterial activity of 1,2-hexanediol

Cited by 17 publications

References 32 publications

Acne treatment efficacy of intense pulsed light photodynamic therapy with topical licochalcone A, l‐carnitine, and decanediol: A spilt‐face, double‐blind, randomized controlled trial

Acne treatment efficacy of intense pulsed light photodynamic therapy with topical licochalcone A, l‐carnitine, and decanediol: A spilt‐face, double‐blind, randomized controlled trial

Topical delivery of niacinamide: Influence of neat solvents

Macelignan inhibits bee pathogenic fungi Ascophaera apis growth through HOG1 pathway

Contact Info

Product

Resources

About